Alcohol-Associated Liver Disease
ALTAltimmune Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Pemvidutide (ALT-801) (GLP-1R/GCGR) in Alcohol-Associated Liver Disease. The expected timing is based on the latest available company guidance and may change.
RESTORE trial. 5/13/25- Initiate trial in Q3 2025. 7/10/25- Phase 2 trial initiated. 11/06/25:- Described RESTORE Phase 2 ALD trial design: 48-week, ~100 patients, pemvidutide versus placebo; study ongoing. 05/13/26:- RESTORE Ph2 ALD trial enrolling; enrollment completion expected Q3 2026. 05/27/26:- RESTORE Ph2 enrollment completion expected Q3 2026; trial began July 2025. 08/12/26:- RESTORE Ph2 enrollment completed. Topline data will be reported in H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.